Oral Vinorelbine in Combination With Capecitabine as a First Line Treatment in Patients (pts) With Metastatic Breast Cancer (MBC) Previously Treated With Anthracyclines ± Taxanes - Preliminary Results of a Multicentric Phase II Trial in Egypt

被引：0

作者：

Kandil, A. ^{[1
]}

Hamada, E. ^{[2
]}

Moawad, M. ^{[3
]}

El Arab, L. Ezz ^{[3
]}

Metwalli, H. ^{[4
]}

Bathiouny, M. ^{[3
]}

Mourad, C. ^{[5
]}

机构：

[1] Alexandria Univ Hosp, Dept Clin Oncol, Alexandria, Egypt

[2] Cairo Univ Hosp, Oncol & Nucl Med Dept, Cairo, Egypt

[3] Ain Shams Univ Hosp, Dept Oncol, Cairo, Egypt

[4] Menofia Univ Hosp, Dept Oncol, Menoufia, Egypt

[5] Pierre Fabre Oncol Middle E, Med Affairs, Beirut, Lebanon

来源：

EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷

关键词：

D O I：

10.1016/S0959-8049(11)71513-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S351 / S351

页数：1

共 50 条

[21] MULTICENTER, PHASE II STUDY OF LAROTAXEL IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC) PROGRESSING AFTER ANTHRACYCLINES, TAXANES AND CAPECITABINE
Ozguroglu, M.
Mansutti, M.
Kerr, R.
Awada, A.
Rha, S. Y.
Im, Y. H.
Perez Manga, G.
Germann, N.
Fumoleau, P.
ANNALS OF ONCOLOGY, 2008, 19 : 69 - 69
[22] Cisplatin-vinorelbine as first line chemotherapy in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes: Results of a retrospective analysis
Raafat, J.
Mourad, C.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : S182 - S182
[23] Phase II study with dose finding of Oral Vinorelbine in combination with Capecitabine as first-line chemotherapy of Metastatic Breast Cancer (MBC): Preliminary results of the phase II part of the study
不详
EJC SUPPLEMENTS, 2006, 4 (02): : 167 - 167
[24] Multicentric phase II trial of gemcitabine plus capecitabine combination in the treatment of previously anthracycline(An)-treated metastatic breast cancer (MBC): SOLTI 0301 study
Ciruelos, E. M.
Baselga, J.
Cortes-Funes, H.
Lluch, A.
Mayordomo, J. I.
Ojeda, B.
Gonzalez, E.
Munoz, M.
Rodriguez, C.
Cortes, J.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[25] Bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Schmid, P
Schippinger, V
Kiewe, P
Lange, W
Preiss, J
Niederle, N
Brossart, P
Freier, W
Van de Velde, H
Possinger, K
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S68 - S69
[26] Phase II study of capecitabine (Xeloda®) in pts with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes.
Fumoleau, P
Largillier, R
Trillet-Lenoir, V
Orfeuvre, H
Extra, JM
Lesimple, T
Culine, S
Montestruc, F
Mouri, Z
Gauducheau, CHR
BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 285 - 285
[27] Triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer (MBC): latest results of an international phase II trial
Chan, A.
Ganju, V.
Becquart, D.
Conte, P. F.
Petruzelka, L.
Perrot, O.
Villanova, G.
Tubiana-Mathieu, N.
EJC SUPPLEMENTS, 2007, 5 (04): : 221 - 222
[28] A phase II trial of capecitabine and vinorelbine as first-line treatment in patients with metastatic breast cancer (BC)
Palumbo, Raffaella
Bernardo, Antonio
Strada, Maria Rosa
Poggi, Guido
Delmonte, Angelo
Teragni, Cristina
Frascaroli, Mara
Bernardo, Giovanni
ANNALS OF ONCOLOGY, 2006, 17 : 75 - 75
[29] Phase II study of single agent oral vinorelbine as a first line treatment for postmenopausal patients with locally recurrent or metastatic breast cancer previously treated with anthracycline or taxanes
Elebrashi, M.
EUROPEAN JOURNAL OF CANCER, 2016, 57 : S113 - S113
[30] A prospective study of vinorelbine and capecitabine combination therapy in patients with metastatic breast cancer pretreated with anthracyclines and taxanes
Xu, B.
Fan, Y.
Tian, L.
Li, Q.
EJC SUPPLEMENTS, 2009, 7 (02): : 283 - 283

← 1 2 3 4 5 →